“Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)”, J of Skin, vol. 4, no. 5, p. s49, Sep. 2020, doi: 10.25251/skin.4.supp.48.